ADL Amdl,

TUSTIN, Calif., Sept. 11 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that at the stockholders' meeting held September 8th, the stockholders approved all of the matters set forth in the Proxy Statement dated July 14, 2006, including the acquisition of Jade Pharmaceuticals Inc. (JPI) and its two wholly owned People's Republic of China-based subsidiaries. The stockholders also approved a number of other proposals increasing the authorized capital stock and approving a reverse split of the outstanding shares. JPI's business activities in China provide AMDL access to the fastest growing pharmaceutical market in the world and an ideal platform to introduce AMDL's DR-70(R) cancer test kits and Combination Immunogene Therapy technology. "We are delighted that the stockholders have overwhelmingly approved the acquisition of JPI and the other matters set forth in the proxy statement. Upon the closing, we will begin implementing the combined business strategy that encompasses the new vision for a U.S. and Asia-Pacific based company," said Gary Dreher, AMDL CEO. Henry Jia, JPI's Director-nominee and Secretary, stated "the completion of this transaction provides a unique opportunity to greatly build on JPI's existing business and creates a strong platform for expansion into the Chinese and Asia-Pacific markets." JPI recently announced that it has obtained China State Food and Drug Administration approval for their drug Ondansetron(R) (Ondansetron Hydrochloride Injection) for immediate use in hospitals and clinics in the People's Republic of China. Ondansetron(R) is highly effective in preventing the emesis and nausea caused by cancer treatments such as radiotherapy and chemotherapy. The new drug works with a patient's dopamine receptors to ameliorate the adverse side effects of radiation and chemotherapies providing better patient comfort, improved recovery times, and accelerated treatment cycles. The global market for drugs to combat chemotherapy-induced nausea and vomiting exceeds $2 billion, according to a study by the Multinational Association of Supportive Care in Cancer. If not prevented, this nausea afflicts 85 percent of cancer patients undergoing chemotherapy and can result in a delay or discontinuation of treatment. JPI has also agreed to cooperate with the gene therapy research team of the Academy of China Military and Medical Sciences (ACMMS). This collaboration will gain powerful support for AMDL's Combination Immunogene Therapy product development in China including clinical trials and a path hopefully leading to Chinese regulatory approval for use in that nation. JPI has also entered into a research and development agreement with New Way Pharmaceuticals of Haikou, Hainan Province, China. New Way will provide use of their research facilities free of charge and the Provincial government has committed to provide land and grants to build a manufacturing base for gene therapy products. The closing of the acquisition is expected to occur on September 28, 2006, concurrently on the effective date of the proposed reverse stock split. At the same time as the closing of the JPI acquisition occurs, all outstanding shares of AMDL Common Stock will be reverse split on a basis to be announced later, but on a no less than one-for-three and no more than a one-for-ten basis, effective 12:01 EDT on September 28, 2006. AMDL's stock will begin trading on the American Stock Exchange on a split-adjusted basis on September 28, 2006. The reverse split, assuming the concurrent closing of the acquisition of JPI, will allow AMDL to become in compliance with AMEX's listing standards. The exercise or conversion price, as well as the number of shares that can be issued, under the Company's outstanding stock options, warrants and convertible securities, will be proportionately adjusted to reflect the reverse stock split. The number of shares reserved for issuance under AMDL's equity compensation plans will also be reduced proportionately. No scrip or fractional share certificates of common stock will be issued in connection with the proposed reverse stock split. Stockholders of record holding a number of shares not evenly divisible by the exact number of shares used in the reverse split formula who would otherwise receive a fractional share of common stock will receive one share of common stock in lieu of each fractional share resulting from the proposed reverse stock split. The stockholders of AMDL are not being asked to exchange the certificates for their existing shares of common stock for certificates for shares of post-reverse split common stock, however they are entitled to do so if they wish. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements The Company intends that the statements in this press release that are not historical constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 of the Securities Exchange Act of 1934, as amended and are subject to numerous risks and uncertainties, including the risks (i) that the transaction described may not be completed when expected, or at all, (ii) the risk that the terms of the definitive acquisition agreements may materially differ from that disclosed herein, (iii) the risks related to the inability to obtain or meet conditions imposed for, governmental and other approvals of the transaction, including the approval by the stockholders of AMDL, (iv) risks related to the uncertainty surrounding the transaction and transactions of this type and (v) the costs related thereto. In addition, these forward-looking statements are subject to the other risks of AMDL's business, including, but not limited to, (a) AMDL's failure to complete successfully the development of new or enhanced products, (b) AMDL's future capital needs, (c) the lack of market demand for any new or enhanced products that AMDL may develop, (d) the lack of market acceptance of AMDL's products and its limited revenues to date, (e) the success of competitive products, other economic factors affecting AMDL and its markets, and (f) other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release in the event of new circumstances or unanticipated events that may occur in the future. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright